SSY GROUP Secures Regulatory Approval for Two Pharmaceutical Products in China

Stock News03-27

SSY GROUP (02005) announced that the company has obtained drug production registration approvals from China's National Medical Products Administration for Sodium Lactate Ringer's Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg). Both products are classified as Category 3 chemical drugs and are considered to have passed consistency evaluations. SSY GROUP's Sodium Lactate Ringer's Irrigation Solution is the first to be approved among domestic manufacturers, primarily intended for general irrigation procedures where sterile electrolyte solutions are applicable. Bumetanide Injection is mainly used to treat edema associated with heart failure and renal or hepatic dysfunction, as well as for preventing acute renal failure and managing conditions including hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug or toxin poisoning. As disclosed in the company's announcement dated March 16, 2026, SSY GROUP's bumetanide active pharmaceutical ingredient had previously received approval from the National Medical Products Administration for use in marketed formulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118108642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118108642","market":"hk","top_or_hot":-1,"title":"SSY GROUP Secures Regulatory Approval for Two Pharmaceutical Products in China","media":"Stock News","content":"<p>SSY GROUP (02005) announced that the company has obtained drug production registration approvals from China's National Medical Products Administration for Sodium Lactate Ringer's Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg). Both products are classified as Category 3 chemical drugs and are considered to have passed consistency evaluations. SSY GROUP's Sodium Lactate Ringer's Irrigation Solution is the first to be approved among domestic manufacturers, primarily intended for general irrigation procedures where sterile electrolyte solutions are applicable. Bumetanide Injection is mainly used to treat edema associated with heart failure and renal or hepatic dysfunction, as well as for preventing acute renal failure and managing conditions including hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug or toxin poisoning. As disclosed in the company's announcement dated March 16, 2026, SSY GROUP's bumetanide active pharmaceutical ingredient had previously received approval from the National Medical Products Administration for use in marketed formulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY GROUP Secures Regulatory Approval for Two Pharmaceutical Products in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY GROUP Secures Regulatory Approval for Two Pharmaceutical Products in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-27 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY GROUP (02005) announced that the company has obtained drug production registration approvals from China's National Medical Products Administration for Sodium Lactate Ringer's Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg). Both products are classified as Category 3 chemical drugs and are considered to have passed consistency evaluations. SSY GROUP's Sodium Lactate Ringer's Irrigation Solution is the first to be approved among domestic manufacturers, primarily intended for general irrigation procedures where sterile electrolyte solutions are applicable. Bumetanide Injection is mainly used to treat edema associated with heart failure and renal or hepatic dysfunction, as well as for preventing acute renal failure and managing conditions including hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug or toxin poisoning. As disclosed in the company's announcement dated March 16, 2026, SSY GROUP's bumetanide active pharmaceutical ingredient had previously received approval from the National Medical Products Administration for use in marketed formulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1118108642","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118108642","pubTimestamp":1774607192,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SSY GROUP (02005) announced that the company has obtained drug production registration approvals from China's National Medical Products Administration for Sodium Lactate Ringer's Irrigation Solution...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团"},"translate_title":"SSY集团两款药品在中国获得监管部门批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY GROUP (02005) announced that the company has obtained drug production registration approvals from China's National Medical Products Administration for Sodium Lactate Ringer's Irrigation Solution (3000ml) and Bumetanide Injection (2ml:1mg). Both products are classified as Category 3 chemical drugs and are considered to have passed consistency evaluations. SSY GROUP's Sodium Lactate Ringer's Irrigation Solution is the first to be approved among domestic manufacturers, primarily intended for general irrigation procedures where sterile electrolyte solutions are applicable. Bumetanide Injection is mainly used to treat edema associated with heart failure and renal or hepatic dysfunction, as well as for preventing acute renal failure and managing conditions including hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, and acute drug or toxin poisoning. As disclosed in the company's announcement dated March 16, 2026, SSY GROUP's bumetanide active pharmaceutical ingredient had previously received approval from the National Medical Products Administration for use in marketed formulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118108642","isCrawlerRequest":true}